Status:
RECRUITING
Correlation Between Serum TK1 and Pathological Remission of Breast Cancer With Neoadjuvant Chemotherapy
Lead Sponsor:
Yunnan Cancer Hospital
Conditions:
Breast Neoplasms
TK1
Eligibility:
FEMALE
18+ years
Brief Summary
The levels and changes of sTK1 among different outcome groups in BCs with different molecular types were compared by stratification to explore whether sTK1 can be used as one of the tumor markers to p...
Detailed Description
Female patients diagnosed with breast cancer by breast biopsy and receiving neoadjuvant chemotherapy in our hospital from 2020 to 2024 were selected as the study objects, and their puncture pathology ...
Eligibility Criteria
Inclusion
- ① The patient was diagnosed with breast cancer by biopsy, and there were complete pathological data. ② Complete the course of neoadjuvant chemotherapy; ③ After the end of neoadjuvant therapy, the operation was performed and the postoperative pathology was obtained; MRI and serum TK1 data were complete (baseline, after 2 cycles of chemotherapy, 4 cycles of chemotherapy, and 6 cycles of chemotherapy).
Exclusion
- ① Distant metastasis at first diagnosis (stage IV); ② With other primary malignant tumors.
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06509555
Start Date
March 1 2024
End Date
February 28 2026
Last Update
July 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yunnan Cancer Hospital
Kunming, Yunnan, China